Learn about China’s biomedical breakthroughs, from cutting-edge pharmaceuticals to life-saving research, driving global health innovation.

BiomedicineChina Future Tech /

Biomedicine

Related Topics:
Companies
Policy
Science
Industry Trends
Geopolitics
Illustration: Henry Wong
New medical drugs

6 of the best: the billion-dollar biotechs putting China on the map

China’s biotech renaissance is gathering pace as home-grown innovators strike billion-dollar licensing deals with global giants.

IPO

China’s Zhipu AI launches US$560 million share sale amid heated IPO tech race

IPO

China vital to Insilico’s plan to build biotech’s AI ‘Einstein’ for new drugs

Made in China 2025

China’s rising biotech clout on show in flurry of billion-dollar licensing deals

A burst of overseas licensing pacts is spotlighting China’s biotech sector, as Jacobio, Coherent Biopharma and Harbour BioMed land deals.

The latest transactions reflect a broader pattern of multinational drugmakers turning to Chinese biotechs for pipeline replenishment. Photo: Shutterstock
The latest transactions reflect a broader pattern of multinational drugmakers turning to Chinese biotechs for pipeline replenishment. Photo: Shutterstock
Banking & finance

Global firms turn to M&A in EVs and biotech to deepen China investment: KPMG

Survey of multinational corporations finds optimism in life sciences, healthcare and manufacturing, with half forecasting revenue growth.

United States

Are Chinese biotechs what the doctor ordered as Big Pharma faces ‘patent cliff’?

US drug makers are racing to plug looming ‘patent cliff’ revenue gaps – and increasingly they are turning to China biotechs.

Advertisement
Advertisement
Advertisement
China’s private sector

BeOne Medicines names R&D chief Wang Lai as president amid global expansion

BeOne generated global revenue of about US$3.8 billion last year, driven by its flagship products Brukinsa and Tevimbra.

BeOne’s manufacturing facility in Guangzhou. Photo: Handout
BeOne’s manufacturing facility in Guangzhou. Photo: Handout
Medicine

Sanofi signs with Hong Kong biotech firm Insilico to spur AI drug discovery

French pharmaceutical giant Sanofi will collaborate with Hong Kong-based biotech firm Insilico Medicine in a deal worth up to US$1.2 billion to speed up the drug-discovery process using artificial intelligence.

videocam
Medicine

Exclusive | Hong Kong’s Insilico, Aramco to partner on sustainable fuels and materials

AI drug discovery unicorn Insilico Medicine is set to sign a deal with Saudi Arabia’s Aramco and a subsidiary during Hong Kong leader John Lee Ka-chiu’s official visit to the country.

videocam
Made in China 2025

China’s pharmaceutical industry transforms into a global innovation powerhouse

The China Pharmaceutical Innovation and Invention Index, a new gauge, highlights top drug makers on the mainland for the first time.

China is gaining a solid reputation as a pharmaceutical innovation hub, according to global consultancy Idea Pharma. Photo: AP
Made in China 2025

China’s new drug insurance: lifeline for patients or squeeze on big firms?

New insurance formulary trims costs of Alzheimer’s and cancer therapies and marks a small win for global novel drug makers.

The commercial insurance formulary covers some medicines that are not yet eligible for reimbursement under the country’s National Reimbursement Drug List. Photo: Shutterstock
The commercial insurance formulary covers some medicines that are not yet eligible for reimbursement under the country’s National Reimbursement Drug List. Photo: Shutterstock
Made in China 2025

Chinese biotech Scizeng’s global licensing deal to yield up to US$1.44 billion

Yarrow Bioscience gets exclusive global rights for the GenSci098 therapy to treat thyroid eye disease and Graves’ disease.

China manufacturing

China’s biotech firms may see ‘major breakthroughs’ within a decade. Here’s why

Strong manufacturing base a driving force behind overseas expansion, but industry leaders and analysts say hurdles remain.

videocam
Made in China 2025

China’s Fosun Pharma unit strikes US$2.1 billion obesity drug deal with Pfizer

Yao Pharma’s deal with the US pharmaceutical giant underscores China’s growing role in global biotech licensing.

The collaboration is “another significant milestone in Fosun Pharma’s strategy of innovation and internationalisation”, according to the company. Photo: Reuters
Banking & finance

From chips to noodles: the newcomers testing Hong Kong’s buoyant IPO market

A wave of billion-dollar offerings is building behind four new listings this week, signalling sustained momentum in Hong Kong’s IPO market.

Guangdong Tianyu Semiconductor plans to raise US$223.42 million at its Hong Kong listing. Photo: Handout
Guangdong Tianyu Semiconductor plans to raise US$223.42 million at its Hong Kong listing. Photo: Handout
Hong Kong stock market

China’s 3SBio seeks US$400 million in Hong Kong to boost drug pipeline

Share placement to help Shenyang-based firm advance clinical research in China and the US, expand reach of cancer and hair-loss drugs.

Shanghai

China bets on bio-manufacturing as new growth engine, bid for tech self-reliance

The pilot-scale platforms are aimed at helping innovators overcome hurdles in R&D and manufacturing before achieving commercial production.

Advertisement
Advertisement
Advertisement
Banking & finance

3SBio spin-off Mandi banks on hair-loss and weight-loss drugs in Hong Kong IPO

As 3SBio lines up a Hong Kong spin-off for its hair-loss unit Mandi, the subsidiary is preparing a drug pipeline aimed at acne and obesity.

The spin-off would result in 3SBio completely exiting its stake in Mandi. Photo: SMCP
The spin-off would result in 3SBio completely exiting its stake in Mandi. Photo: SMCP
Biomedicine: Industry Trends

China’s clinical trial capacity matches US, attracts more global pharma firms

Growth of innovative clinical trials suggests that Chinese biotech firms’ pipeline of novel drug candidates is expanding, analysts say.

Made in China 2025

‘Significant gains’: US review evaluates ‘Made in China 2025’ advancements

The decade-long strategy reduces strategic vulnerabilities and strengthens geopolitical leverage, congressional report finds.

videocam
17
IPO

Chinese drug developer Biokin postpones Hong Kong listing

Decision likely reflects ‘some pullback in risk appetite, with growth-stock share prices coming off their highs’, Morningstar analyst says.

Share prices of Chinese biotech companies have declined this quarter, according to a Morningstar analyst. Photo: Shutterstock
China manufacturing

China’s southwestern industrial base eyes breakthroughs on novel drugs

As country pushes for scientific and technological self-reliance, Chongqing will provide support for pharmaceutical research and development.

Tablets and capsules made using key pharmaceutical ingredients from China. Photo: DPA
Tablets and capsules made using key pharmaceutical ingredients from China. Photo: DPA
China manufacturing

China’s ‘smart healthcare’ firms draw crowds as Canton Fair wraps up

While Chinese medical technology companies are gaining market share, insiders said trust still needs to be built for global success.

videocam
Greater Bay Area

BeOne Medicines to expand cancer-drug offerings in Hong Kong

Fresh off a profitable half year, a global drug company that started as an R&D firm in Beijing plans to expand production in Guangzhou.

Hong Kong stock market

China’s Akeso gets share boost as data shows cancer drug’s benefits

Lung-cancer drug ivonescimab is ‘potentially two to three years ahead of competitors’, analyst says.

Trial showed “a decisive and strong positive outcome with both significant and clinically meaningful benefits”, Akeso said. Photo: Shutterstock
Help preserve 120 years of quality journalism.
SUPPORT NOW